Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy

2014-08-27 03:12:25 | BioPortfolio


Recently, adalimumab has been authorized for active psoriasis in Peru and local experience is very low. The aim of this study is to obtain Peruvian data of clinical effectiveness; and impact in the health related quality of life with the use of Adalimumab in psoriatic patients complying with the dosing and monitoring recommendations of the local approved label.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Moderate to Severe Psoriasis


Not yet recruiting



Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:12:25-0400

Clinical Trials [1896 Associated Clinical Trials listed on BioPortfolio]

Open Label Continuation Study in Moderate to Severe Psoriasis

Long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis

The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)

This is a Phase 3b, randomized, parallel-group, multicenter, active-controlled, open-label study of the efficacy and safety of infliximab compared with methotrexate (MTX) in the treatment ...

Study of BMS-587101 in Patients With Moderate to Severe Psoriasis

The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.

A Registry of Patients With Moderate to Severe Plaque Psoriasis

The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe c...

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

The purpose of this clinical research study is to learn if BMS-582949 alone is an effective treatment for moderate to severe psoriasis. The safety of the drug and the effectiveness of eac...

PubMed Articles [6870 Associated PubMed Articles listed on BioPortfolio]

Risk of serious infection, opportunistic infection and herpes zoster among patients with psoriasis in the United Kingdom.

The risk of infection among patients with psoriasis of varying severity in a broadly representative population remains poorly understood. Using The Health Improvement Network (THIN), an electronic med...

Benefit-risk of tofacitinib in patients with moderate to severe chronic plaque psoriasis: Pooled analysis across 6 clinical trials.

Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibi...

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States.

Clinical trials have shown brodalumab to have better efficacy than ustekinumab for the treatment of moderate-to-severe psoriasis. An estimation of the cost-effectiveness of brodalumab vs. ustekinumab ...

Comparative Effectiveness of Targeted Immunomodulators for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis.

The comparative effectiveness of available targeted immunomodulators for moderate-to-severe psoriasis has not been evaluated.

Comprehensive Long-Term Safety of Adalimumab from Eighteen Clinical Trials in Adult Patients With Moderate to Severe Plaque Psoriasis.

Adalimumab (Humira ; AbbVie Inc., USA) is a fully human monoclonal antibody specific for tumour necrosis factor-α approved to treat adults with moderate-to-severe chronic plaque psoriasis.

Medical and Biotech [MESH] Definitions

A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.

An opioid analgesic used similarly to MORPHINE in the control of moderate to severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1097)

For-profit enterprise with relatively few to moderate number of employees and low to moderate volume of sales.

A group of tetraterpenes, with four terpene units joined head-to-tail. Biologically active members of this class are used clinically in the treatment of severe cystic ACNE; PSORIASIS; and other disorders of keratinization.

Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation, visual impairment, or blindness.

More From BioPortfolio on "Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy"

Quick Search


Relevant Topic

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Searches Linking to this Trial